Year All2026202520242023 Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF May 27, 2025 Read more Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference May 19, 2025 Read more Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 15, 2025 Read more Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF May 12, 2025 Read more Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF May 1, 2025 Read more Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 April 30, 2025 Read more Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference April 28, 2025 Read more Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases April 23, 2025 Read more Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F April 15, 2025 Read more Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update April 7, 2025 Read more
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF May 27, 2025 Read more
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference May 19, 2025 Read more
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 15, 2025 Read more
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF May 12, 2025 Read more
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF May 1, 2025 Read more
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference April 28, 2025 Read more
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases April 23, 2025 Read more
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F April 15, 2025 Read more
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update April 7, 2025 Read more
